Jafron Biomedical Co Ltd (SHE:300529) — Market Cap & Net Worth
Market Cap & Net Worth: Jafron Biomedical Co Ltd (300529)
Jafron Biomedical Co Ltd (SHE:300529) has a market capitalization of $1.83 Billion (CN¥12.54 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #6604 globally and #1444 in its home market, demonstrating a -5.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jafron Biomedical Co Ltd's stock price CN¥15.70 by its total outstanding shares 798605275 (798.61 Million). Review Jafron Biomedical Co Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
Jafron Biomedical Co Ltd Market Cap History: 2016 to 2026
Jafron Biomedical Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $2.63 Billion to $1.83 Billion (7.86% CAGR).
Index Memberships
Jafron Biomedical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.43 Trillion | 0.13% | #88 of 100 |
Weight: Jafron Biomedical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jafron Biomedical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jafron Biomedical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.14x
Jafron Biomedical Co Ltd's market cap is 1.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.31x
Jafron Biomedical Co Ltd's market cap is 4.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.63 Billion | $543.64 Million | $202.12 Million | 4.84x | 13.01x |
| 2017 | $1.79 Billion | $718.49 Million | $284.41 Million | 2.50x | 6.31x |
| 2018 | $2.35 Billion | $1.02 Billion | $401.98 Million | 2.31x | 5.85x |
| 2019 | $4.11 Billion | $1.43 Billion | $570.82 Million | 2.87x | 7.20x |
| 2020 | $7.43 Billion | $1.95 Billion | $875.24 Million | 3.81x | 8.49x |
| 2021 | $5.88 Billion | $2.68 Billion | $1.20 Billion | 2.20x | 4.91x |
| 2022 | $3.48 Billion | $2.49 Billion | $889.56 Million | 1.40x | 3.92x |
| 2023 | $2.56 Billion | $1.92 Billion | $436.49 Million | 1.33x | 5.87x |
| 2024 | $3.43 Billion | $2.68 Billion | $820.20 Million | 1.28x | 4.18x |
| 2025 | $2.30 Billion | $2.01 Billion | $532.82 Million | 1.14x | 4.31x |
Competitor Companies of 300529 by Market Capitalization
Companies near Jafron Biomedical Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Jafron Biomedical Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #147 globally with a market cap of $153.73 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #207 globally with a market cap of $117.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #234 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #247 globally with a market cap of $101.86 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #147 | Abbott Laboratories | NYSE:ABT | $153.73 Billion | $88.41 |
| #207 | Stryker Corporation | NYSE:SYK | $117.79 Billion | $307.80 |
| #234 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #247 | Medtronic PLC | NYSE:MDT | $101.86 Billion | $79.34 |
Jafron Biomedical Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Jafron Biomedical Co Ltd's market cap moved from $2.63 Billion to $ 1.83 Billion, with a yearly change of 7.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.83 Billion | -20.18% |
| 2025 | CN¥2.30 Billion | -32.96% |
| 2024 | CN¥3.43 Billion | +33.90% |
| 2023 | CN¥2.56 Billion | -26.52% |
| 2022 | CN¥3.48 Billion | -40.74% |
| 2021 | CN¥5.88 Billion | -20.86% |
| 2020 | CN¥7.43 Billion | +80.71% |
| 2019 | CN¥4.11 Billion | +74.78% |
| 2018 | CN¥2.35 Billion | +31.20% |
| 2017 | CN¥1.79 Billion | -31.80% |
| 2016 | CN¥2.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Jafron Biomedical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.83 Billion USD |
| MoneyControl | $1.83 Billion USD |
| MarketWatch | $1.83 Billion USD |
| marketcap.company | $1.83 Billion USD |
| Reuters | $1.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machi… Read more